Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSC-exosome-loaded dendritic cell vaccine and activated CTL therapy for hepatocellular carcinoma and other solid tumors
ChiCTR1800020076Phase 2Not yet recruiting
- Sponsor
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Start
- Jan 2019
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of cancer stem cell exosome-loaded dendritic cell vaccine in hepatocellular carcinoma (HCC) and Nonhematologic neoplasms (4 arms), sponsored by Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine. Primary endpoints: objective response rate, progression-free survival and 6 more. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
cancer stem cell exosome-loaded dendritic cell vaccine
03
Conditions
hepatocellular carcinoma (HCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR1800020076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020076.